Compare SDGR & BST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDGR | BST |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | N/A | N/A |
| Metric | SDGR | BST |
|---|---|---|
| Price | $11.88 | $39.62 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $24.33 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 98.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.74% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.91 | N/A |
| Revenue Next Year | $19.40 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.15 | $27.87 |
| 52 Week High | $28.47 | $44.50 |
| Indicator | SDGR | BST |
|---|---|---|
| Relative Strength Index (RSI) | 28.49 | 44.70 |
| Support Level | $11.15 | $38.81 |
| Resistance Level | $13.94 | $41.10 |
| Average True Range (ATR) | 0.75 | 0.79 |
| MACD | -0.13 | -0.09 |
| Stochastic Oscillator | 20.81 | 38.34 |
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
BlackRock Science and Technology Trust is a closed-end management investment company. Its investment objective is to provide income and total return through a combination of current income, current gains, and long-term capital appreciation. It focuses on investing, under a normal market condition in equity securities of science and technology companies.